Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts where she shares investment power, exercised 9,500 stock options at a strike price of $135.42 to acquire the same number of common shares, then sold 9,500 shares in several open-market or private transactions at weighted average prices in the low $520s per share. The option exercise and related sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026.
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and, on July 29, 2026, sold the resulting 9,500 shares in multiple open-market transactions under a pre-arranged 10b5-1 trading plan adopted November 7, 2025.
After this exercise, a family trust reported holding 246,410 stock options expiring March 15, 2027, while Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly through a spouse, along with additional share holdings in family trusts.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28. The trades were executed under a pre-arranged 10b5-1 trading plan adopted November 7, 2025 that covers up to 1,734,410 options expiring March 15, 2027. Following the exercise, a family trust holds 255,910 options, and Rothblatt reports 40,513 shares directly and 166 shares indirectly via her spouse, along with additional family-trust holdings.
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 and acquired 9,500 common shares on July 27, 2026. Those shares were then sold in multiple trades totaling 9,500 shares at prices between about $526 and $535 per share under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. Following the exercise, a trust reports 265,410 options remaining, as part of up to 1,734,410 options covered by the plan and expiring March 15, 2027, while separate entries show 40,513 shares held directly and 166 shares held indirectly by spouse.
United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that family trusts with which she shares investment power exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock on July 24, 2026 at weighted-average prices between approximately $528 and $535 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following the exercise, the trusts continue to hold 274,910 stock options from this grant expiring March 15, 2027, and Rothblatt also directly owns 40,513 common shares. The trading plan will continue until the earlier of the exercise of up to 1,734,410 stock options or December 31, 2026.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on 2026-07-23 and sold the resulting 9,500 shares in multiple transactions at prices between $522.31 and $531.94 per share.
The options, expiring March 15, 2027, are covered by a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of exercising 1,734,410 options or December 31, 2026. After this exercise, 284,410 options remain held indirectly by a family trust, and Rothblatt also holds 40,513 shares directly and 166 shares indirectly through a spouse.
United Therapeutics Corporation director Victor J. Dzau reported equity awards received on July 22, 2026 in connection with his appointment to the Board. He was granted 730 restricted stock units and 2,300 stock options under the Non-Employee Director Compensation Program. Each RSU represents one share of common stock upon vesting. The stock options cover common stock at an exercise price of $527.0700 per share, vest on the one-year anniversary of the grant date, and expire on July 22, 2033.
United Therapeutics Corp director Victor J. Dzau has filed an initial Form 3, establishing him as a reporting person for UTHR equity. Disclosed information shows he is a director, not an officer or ten percent owner, and that no insider transactions or derivative positions are reported.
United Therapeutics granted director Linda Maxwell annual non-employee director equity awards on 2026-07-22, consisting of 380 restricted stock units and 1,190 stock options on common stock. The options carry a $527.0700 exercise price and expire on 2033-07-22.
Each restricted stock unit represents one share of common stock after vesting and has no expiration date. Both awards become fully vested on the earlier of one year from grant or the anticipated June 25, 2027 Annual Meeting of Shareholders. No sales or dispositions were reported.
United Therapeutics Corporation director Tommy G Thompson received equity compensation on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options with an exercise price of $527.07 per share.
The awards, described as an annual non-employee director grant, vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, with June 25, 2027 noted as the anticipated meeting date. Each restricted stock unit represents the right to receive one share of common stock after vesting and has no expiration date.
After these awards, Thompson holds 8,480 United Therapeutics common shares directly (including 880 issued from previously deferred RSUs), plus 8,200 shares held indirectly by a trust and 5,800 shares held indirectly through a family LLC.